is compounded semaglutide or tirzepatide better & 2025: Safe Use Guide Standard Dose vs Microdose GLP-1:

A 2025 perspective proposed that GLP-1s could influence epigenetic pathways involved in fibrosis and hepatocellular carcinoma risk in the aging liver [6]

By contrast, countries like India, which do not award patent term extensions, could see generic competition entering much sooner once the patents on the main compound expire there in 2026

Randomized, double-blind, placebo-controlled, and replicated is strong

Patient retention rates average 78% at six months, with most discontinuations due to cost rather than efficacy concerns

Clinical Implementation Challenges Patient Selection and Individualization The importance of individualized dosing and patient assessment to optimize safety and efficacy [68] [69] [70] represents a key implementation challenge

Many people experience mild gastrointestinal symptoms during dose escalation, which often improve as the body adjusts to treatment